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MEETING REPORT
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in the Asia–Pacific region
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Huynh Hong Quang11, Nancy Dian Anggraeni12, Ferdinand Laihad13, Yaobao Liu14, Maria Endang Sumiwi13, 
Hidayat Trimarsanto1, Farah Coutrier1, Nadia Fadila1, Najia Ghanchi15, Fatema Tuj Johora16, 
Agatha Mia Puspitasari1, Livingstone Tavul17, Leily Trianty1, Retno Ayu Setya Utami1, Duoquan Wang18, 
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Abstract 
The Asia–Pacific region faces formidable challenges in achieving malaria elimination by the proposed target in 2030. 
Molecular surveillance of Plasmodium parasites can provide important information on malaria transmission and adap‑
tation, which can inform national malaria control programmes (NMCPs) in decision‑making processes. In November 
2019 a parasite genotyping workshop was held in Jakarta, Indonesia, to review molecular approaches for parasite 
surveillance and explore ways in which these tools can be integrated into public health systems and inform policy. 
The meeting was attended by 70 participants from 8 malaria‑endemic countries and partners of the Asia Pacific 
Malaria Elimination Network. The participants acknowledged the utility of multiple use cases for parasite genotyping 
including: quantifying the prevalence of drug resistant parasites, predicting risks of treatment failure, identifying major 
routes and reservoirs of infection, monitoring imported malaria and its contribution to local transmission, character‑
izing the origins and dynamics of malaria outbreaks, and estimating the frequency of Plasmodium vivax relapses. 
However, the priority of each use case varies with different endemic settings. Although a one‑size‑fits‑all approach 
to molecular surveillance is unlikely to be applicable across the Asia–Pacific region, consensus on the spectrum of 
added‑value activities will help support data sharing across national boundaries. Knowledge exchange is needed 
to establish local expertise in different laboratory‑based methodologies and bioinformatics processes. Collaborative 
research involving local and international teams will help maximize the impact of analytical outputs on the opera‑
tional needs of NMCPs. Research is also needed to explore the cost‑effectiveness of genetic epidemiology for differ‑
ent use cases to help to leverage funding for wide‑scale implementation. Engagement between NMCPs and local 
researchers will be critical throughout this process.
Keywords: Plasmodium falciparum, Plasmodium vivax, Malaria, Surveillance, Molecular surveillance, Genotyping, 
Genomics, SNP barcode
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/




9 Global and Tropical Health Division, Menzies School of Health Research 
and Charles Darwin University, Darwin, NT, Australia
Full list of author information is available at the end of the article
Page 2 of 20Noviyanti et al. Malar J          (2020) 19:271 
Background
Malaria remains a major public health burden in the 
Asia–Pacific region, with an estimated 10 million cases 
and 15 thousand deaths in 2018 [1]. Nonetheless, there 
has been a substantial decline in malaria cases over the 
last 2 decades, that has enabled national malaria control 
programmes to start implementing strategies for malaria 
elimination. In 2009, the Asia Pacific Malaria Elimination 
Network (APMEN) was established to address the unique 
challenges of malaria elimination in the region, through 
knowledge exchange, capacity strengthening and build-
ing the evidence base for elimination [2, 3]. Several years 
later, the Asia Pacific Leaders Malaria Alliance (APLMA) 
was formed to enhance and streamline regional response 
to malaria, with the goal of eliminating this disease from 
the region by 2030. However, the challenges to achieve 
this goal are considerable.
The revolution in genomic technologies has cre-
ated new opportunities to study how malaria parasites 
adapt and spread within and across borders and has the 
potential to help answer key epidemiological questions 
that could help NMCPs form better elimination strate-
gies. However, there are currently significant obstacles 
preventing wide adoption of molecular technologies to 
endemic countries and their integration into national 
public health systems. Recent reviews have discussed 
the challenges of integrating genomic surveillance for 
malaria in Africa [4–6]; similarly, the authors sought to 
dissect the challenges hindering the adoption of genomic 
technology in the Asia–Pacific region. Although the bur-
den of malaria in the Asia–Pacific region is considerably 
lower than that in Africa, the region faces additional chal-
lenges of a high proportion of non-falciparum malaria, as 
well as being the epicentre of the emergence of resistance 
against frontline anti-malarials, such as artemisinin and 
its partner drugs [7–10].
In November 2019, the Menzies School of Health 
Research (Menzies), in collaboration with the Eijkman 
Institute for Molecular Biology (Eijkman), conducted a 
two-day parasite genotyping workshop in Jakarta, Indo-
nesia. The concept for the workshop stemmed from dis-
cussions within APMEN around the need to address the 
challenges of parasite genetic surveillance in the region. 
As a result, APMEN participants from 21 countries, as 
well as several self-funded collaborators were invited 
to join the 2  day workshop, which was co-funded by 
APMEN, the Australian Department of Foreign Affairs 
and Trade (DFAT) and the Australian Center of Research 
Excellence in Malaria Elimination (ACREME). The meet-
ing was attended by 70 participants, with representatives 
from 8 malaria-endemic countries in the Asia–Pacific 
region; Bhutan, Bangladesh, Pakistan, Thailand, Vietnam, 
China, Indonesia and Papua New Guinea. Participants 
included representatives of NMCPs, researchers, United 
Nations Children’s Fund (UNICEF) and the World Health 
Organization (WHO). The aim of the workshop was to 
review recent advances in molecular approaches for Plas-
modium falciparum and Plasmodium vivax parasite sur-
veillance and explore ways in which novel surveillance 
strategies could be integrated into policy and practice.
This reports key messages, with specific focus on the 
following topics:
 I. Use cases for parasite genotyping in surveillance.
 II. Technical challenges in implementing genotyping 
in-country.
 III. Data sharing within and between countries.
 IV. Maximizing the value of parasite genotyping for 
NMCPs.
Use cases for parasite genotyping in surveillance
Dr Sarah Auburn, from Menzies, gave an overview of use 
cases for genetic epidemiology that support the opera-
tional needs of NMCPs [11], and led discussions centred 
around assessing their local utility, as well as identifying 
new relevant use cases.
Detect resistance
Following the widespread failure of chloroquine and 
sulfadoxine-pyrimethamine (SP) treatments against P. 
falciparum, the implementation of artemisinin-based 
combination therapy (ACT) in the early-to-mid 2000s 
has been a major contributor to the remarkable success in 
case reductions in the Asia–Pacific region [1]. Therefore, 
the emergence and spread of P. falciparum strains resist-
ant to artemisinin and some of its ACT partner drugs in 
the Greater Mekong subregion (GMS) is a major concern 
that has elicited an emergency response to contain fur-
ther spread. Clinical, laboratory and molecular studies 
have identified that mutations in the k13 gene located on 
chromosome 13 of P. falciparum determine and modu-
late resistance to artemisinin [12–14]. Although multi-
ple k13 mutations have been associated with artemisinin 
resistance, the C580Y mutation has become dominant 
in the GMS in the last few years [15]. Mutations associ-
ated with resistance to ACT partner drugs have become 
widespread, including copy number amplifications of 
the plasmepsin 2/3 genes (pfpm2/pfpm3) and the multi-
drug resistance 1 gene (pfmdr1), which confer resistance 
to piperaquine and mefloquine respectively [16–18]. 
Genetic correlates of parasite resistance to several com-
monly used anti-malarials in the Asia–Pacific region are 
summarized in Table 1. The malaria Genomic Epidemi-
ology Network (malariaGEN) community has developed 
a set of rules for classifying parasites in terms of drug 
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resistance, based on the alleles detected at these markers 
[19].
Surveillance of P. falciparum drug resistance was 
raised as one of the highest priorities of participants 
from high and intermediate transmission regions in the 
GMS and other areas. Until recently, there was no con-
vincing evidence of artemisinin resistance in the Pacific 
region. Olivo Miotto from the Mahidol Oxford Research 
Unit (MORU), Thailand, described the recent detection 
of three P. falciparum infections in Wewak, Papua New 
Table 1 Summary of genetic correlates of drug resistance in P. falciparum and P. vivax 
Countries are listed using two letter codes BD Bangladesh, BT Bhutan, KH Cambodia, CN China, IN India, ID Indonesia, KP DPR of Korea, KR Rep. of Korea, LA Lao PDR, 
MY Malaysia, MM Myanmar, NP Nepal, PH Philippines, PG PNG, SB Solomon Is., TH Thailand, TL Timor-Leste, VN Vietnam, VU Vanuatu
a Countries in the Asia–Pacific region where the given anti-malarial drug is implemented as national drug policy (alone or in combination) for treatment of 
uncomplicated unconfirmed, uncomplicated confirmed or severe P. falciparum or P. vivax infection, or for intermittent preventative treatment in pregnant women 
(IPT) [1]
Species Anti-malarial Country (policy)a Gene Validated mutations Associated mutations References
P. falciparum Artemisinin derivatives BD, BT, KH, CN, ID, IN, LA, 
MY, MM, NP, PH, PG, SB, 
TH, TL, VU, VN
pfkelch13 Y493H, R539T, I543T, 
R561H, C580Y
P441L, F446I, G449A, 
N458Y, M476I, N537D, 
P553L, V568G, P574L, 
M579I, D584V, A675V, 
H719N
[12, 13]
Piperaquine CN, ID, MM, TH, VN pfpm2/pfpm3  ≥ 2 copies of the gene – [16, 17]
Mefloquine KH, MY, MM pfmdr1  ≥ 2 copies of the gene S1034C, N1042D [18, 83, 84]
Lumefantrine BD, BT, CN, ID, LA, MM, NP, 
PH, PG, SB., TL, VU
pfmdr1 – N86Y, [85, 86]
Chloroquine ID, KR, SB (IPT), VU (IPT) pfcrt K76T with; M74I and N75E, 
or C72S
– [87]
pfmdr1 – N86Y, S1034C, N1042D, 
D1246Y
[84, 88]
Sulfadoxine ID, PG (IPT) pfdhps S436A, K437G, K540E, 
A581G, A613S/T
– [89, 90]
Pyrimethamine PG (IPT) pfdhfr C50R, N51I, C59R, S108N, 
I164L
– [89]
Amodiaquine CN pfcrt C72S and K76T – [91]
pfmdr1 – N86Y, D1246Y [81, 91]
Pyronaridine CN – – – –
Primaquine ID, IN, LA, NP, PH – – – –
Quinine BD, BT, KH, ID, IN, MY, MM, 
PH, KR, SB, TL, VN
– – – –
P. vivax Chloroquine BD, BT, CN, KP, ID, MM, NP, 
PH, KR, SL, TH, VN
pvcrt-o – Increased expression, 
14 TGAAGH motifs in 
intron 9
[25, 26]
Intergenic – 15 TGAAGH motifs at 
MS334 (upstream of 
pvcrt‑o)
[26]
pvmdr1 – Increased expression, 
Y976F, F1076L
[25, 92, 93]
Sulfadoxine – pvdhps – A383G, A553G [94, 95]
Pyrimethamine – pvdhfr – F57L, S58R, T61M, S117T, 
S117N
[96–101]
Mefloquine KH, MY pvmdr1 –  ≥ 2 copies of the gene [102–104]
Amodiaquine – pvmdr1 – Y976F [96]
Artemisinin derivatives KH, IN, LA, MY, PH, PNG, 
SB, TL, VU
– – – –
Piperaquine CN, IN – – – –
Lumefantrine LA, MY, PH, PG, SB, TL, VU – – – –
Primaquine BD, BT, KH, CN, KP, ID, IN, 
LA, MY, MM, NP, PH, PG, 
KR, SB, TH, TL, VU, VN
– – – –
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Guinea (PNG) [118], which carried C580Y mutations on 
a genetic background distinct from that observed in the 
GMS, highlighting the importance of vigilance across the 
region. Alyssa Barry from Deakin University, Australia, 
presented data on behalf of STRIVE (Stronger Surveil-
lance and Systems Support for Rapid Identification and 
Containment of Resurgent or Resistant Vector Borne 
Pathogens) PNG, an international team including the 
PNG NMCP and PNG Institute of Medical Research, 
showing that these mutations had not yet spread to other 
parts of the country, and no clinical resistance has been 
detected.
Molecular surveillance of determinants of anti-malar-
ial drug resistance was acknowledged as an important 
early warning system to identify hotspots of resistance, 
prioritizing where therapeutic efficacy surveys should 
be conducted, and informing on which alternative treat-
ment regimens could be effective in areas with high lev-
els of failures against the current frontline treatment. 
Nguyen Thuy-Nhien from the Oxford University Clinical 
Research Unit (OUCRU), Vietnam, described large-scale 
molecular surveillance at 50 sites in 9 provinces of Viet-
nam, implemented as part of the GenRe-Mekong project 
in close collaboration with the NMCP. This implementa-
tion leverages on SpotMalaria (https ://www.malar iagen 
.net/proje cts/spotm alari a), a technology framework 
providing high-throughput genotyping of malaria para-
sites at a broad selection of single nucleotide polymor-
phisms (SNPs). SpotMalaria genotypes all k13 mutations, 
pfpm2/pfpm3 amplifications, and most important mark-
ers of resistance to current and historical drugs, as well 
as a genetic barcode of 101 neutral SNPs and variants 
informative of co-infecting species. Since the project’s 
establishment in 2017, information provided by GenRe-
Mekong, in collation with clinical data, has contributed 
to anti-malarial drug policy changes in two provinces in 
Vietnam, underscoring the great translational utility of 
this genotyping use case.
In many Asia–Pacific countries, chloroquine is still 
the recommended first-line treatment for blood stage P. 
vivax. In Cambodia, Indonesia, Malaysia, PNG, Vanuatu 
and Solomon Islands, high rates of chloroquine failure 
against P. vivax have led to a policy change towards ACT 
as first-line treatment for all species of malaria [20–22]. 
Jutta Marfurt, from Menzies, gave an overview of anti-
malarial drug resistance in P. vivax, emphasizing the lack 
of validated molecular markers of clinical chloroquine or 
artemisinin resistance in this parasite (Table 1).
Although the Y976F mutation in the P. vivax multid-
rug resistance 1 gene (pvmdr1) is frequently genotyped 
in research studies, this variant is a minor modulator 
of chloroquine sensitivity and, therefore, not informa-
tive in the absence of phenotypic data from clinical or 
laboratory studies [23]. The role of the P. vivax chloro-
quine resistance transporter gene (pvcrt-o) also remains 
unclear, with conflicting patterns of association between 
pvcrt-o expression and chloroquine susceptibility 
observed in field studies [24, 25]. A repeat-length poly-
morphism associated to changes in pvcrt-o expression 
has recently been identified in a laboratory-based study, 
but further evaluation is needed in patients with clini-
cal disease before it is used as a marker of chloroquine 
resistance [26]. The absence of molecular markers for 
P. vivax remains a major gap in molecular surveillance 
frameworks.
Assess drug resistance gene flow
Identifying reservoirs of drug resistant strains, and the 
routes through which they spread, within and across bor-
ders, can help NMCPs to map the geographical areas at 
greatest risk of treatment failures, and plan suitable inter-
ventions and alternative treatment strategies. Genetic 
data on malaria parasites can provide deep insights on 
the origins and genetic make-up of drug resistant vari-
ants, and the lineages that carry them. Combining newly 
generated and publicly available whole genome sequenc-
ing data, Miotto and colleagues were able to demonstrate 
that the three PNG C580Y mutants in Wewak were not 
imported from the GMS; rather, they shared close genetic 
relatedness to Papua Indonesian isolates and carried a 
C580Y mutation that has arisen independently [118]. 
An alternative approach to whole genome sequencing is 
genotyping highly polymorphic markers in the regions 
flanking the drug resistance variant(s); for example, 
Imwong and colleagues used flanking microsatellites to 
reconstruct the routes of spread of a C580Y mutant lin-
eage in the GMS [27]. However, aligning microsatellite-
based datasets generated by different groups can be 
difficult, and artefacts such as stutter can be problematic 
for reliable genotype calling [28]. An informative SNP 
panel needs to be developed to enable a high-throughput 
approach for monitoring gene flow.
Assess transmission intensity
Determining transmission intensity is critical for 
NMCPs to monitor progress and optimize interven-
tion strategies in different areas; for instance, to iden-
tify where to focus resources for interrupting residual 
transmission and minimizing the risk of imported 
parasites in areas close to malaria elimination. Tradi-
tional surveillance methods incorporating tools such 
as microscopy and rapid diagnostic tests (RDTs) can 
gauge the prevalence or incidence of infections but rely 
on local treatment-seeking behaviour and diagnostic 
accuracy. Amplification of parasite DNA, such as Pol-
ymerase Chain Reaction (PCR), improves diagnostic 
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sensitivity but is still reliant on effective methods for 
detecting infected individuals. Parasite genotyping has 
been proposed as a complementary method to pro-
vide information on the parasite population dynamics 
in a given area, by estimating indices of transmission 
intensity from genetic data. In some endemic settings, 
the frequency of polyclonal infections or complex-
ity of infection (COI) are good correlates of transmis-
sion intensity [29], since polyclonal infections are more 
commonly observed in high transmission areas, where 
more infected mosquitoes provide greater opportunity 
for superinfection. However, such relationships are not 
necessarily observed in all settings, possibly because of 
imported infections [30, 31], differences in sampling 
methods [32], or differing marker sets or genotype call-
ing methods. Several statistical methods are available 
to estimate polyclonality: for instance, Multiplicity of 
Infection (MOI) is often applied to microsatellite-based 
datasets, within-sample fixation index (FWS) to genomic 
SNP datasets, and the likelihood-based COIL method 
for measuring COI using SNP barcodes [28, 33, 34]. 
Several genotyping platforms are available for assess-
ing COI. Traditionally, parasite genotyping has used 
PCR to amplify gene regions with repeat-length poly-
morphisms, such as the P. falciparum merozoite surface 
proteins 1 and 2 (pfmsp1 and pfmsp2) and orthologous 
P. vivax gene families or microsatellites [35–39]. Multi-
ple clone infections can be detected by the presence of 
multiple PCR amplicons of differing lengths as detected 
by investigation of band patterns on agarose gels or cap-
illary sequencing. In recent years, deep sequencing of a 
targeted selection of highly diverse gene regions using 
amplicon sequencing on massively parallel sequencing 
platforms such as Illumina, has become the favoured 
approach to characterize the complexity of malaria 
infections [40]. The extensive depth of sequence reads 
generated by amplicon deep sequencing (100–1000  s 
of reads per target gene depending on the sequencing 
conditions) enables substantially greater sensitivity to 
detect minor clones than capillary sequencing. Stud-
ies in PNG, where transmission is high and infections 
are frequently complex, have demonstrated the detec-
tion of minor P. falciparum clones at a detection limit 
of 1:1000, and used these methods to track longitudi-
nal infection dynamics with high sensitivity [41–43]. 
Amplicon deep sequencing has also been used in P. 
vivax to compare infection dynamics between day 0 
and recurrent infections [44]. Several analysis tools 
have been developed to support the analysis of infec-
tion complexity using deep sequencing data, including 
PASEC, DADA2, HaplotypR and SeekDeep [43, 45–
47]. Despite differences in their approach, these four 
state-of-the-art tools resolved known haplotype mix-
tures with similar sensitivity and precision [47].
The study of genetic relatedness and population struc-
ture can also be informative of transmission levels: stud-
ies of both P. falciparum and P. vivax have observed 
increasing genetic relatedness between infections as 
parasite populations dwindle, as inbreeding and clonal 
transmission becomes predominant [48–53]. Shrinking 
populations tend to form moderately distinct pockets (or 
foci) of infection, which translate to changes in popula-
tion structure, often modulated by external factors. In 
contrast to conventional methods such as microscopy or 
RDTs, genetic indices require representative sampling, 
but are not reliant on comprehensive sampling, which 
makes them potentially robust tools for assessing trans-
mission intensity.
An example of the use of endemicity data by NMCPs 
was provided by Nancy Dian Angraenni from the Min-
istry of Health, Indonesia. She outlined the “island by 
island” malaria elimination strategy in Indonesia, where 
areas are categorized according to the local endemic-
ity, and control activities are applied in stages from the 
regency/city administrative levels to the provincial and 
then regional and national levels. These efforts require 
detailed maps of malaria risk to guide the strategic dis-
tribution of limited resources, with regular updates as 
control progresses [54]. A better understanding of how 
genetic indices correlate with malaria elimination cat-
egories will help to stratify interventions in areas where 
regular and comprehensive surveillance by conventional 
methods is not feasible.
Identify foci of infection
This use case defines target areas for tailored interven-
tions; examples include localizing hotspots of transmis-
sion in heterogenous regions, or residual transmission 
foci in low endemic areas. This is not a high priority in 
high transmission areas, where infections tend to be uni-
formly distributed and distinct foci of infection are gen-
erally rare [55]. However, as transmission declines and 
parasite populations shrink, distinct foci of infection 
begin to emerge. These are currently identified from geo-
spatial surveillance and case investigations, but detection 
can be improved by comparing the parasite genetic relat-
edness within versus between foci [11]. Further research 
is needed to determine operationally relevant spatial 
scales for defining the boundaries of foci, and the stability 
of these foci over time.
Determine connectedness between parasite populations
Estimating the connectedness between parasite popu-
lations can help gauge the risks of parasites spread-
ing between geographic areas. This information is 
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particularly important for locating major reservoirs 
(“sources”) that are sustaining infections in other areas 
(“sinks”). Connectedness can be estimated using human 
mobility data, such as patient travel history or mobile 
phone data, but two recent studies highlight the poten-
tial of combining these data with parasite genetic data, to 
reveal both local and long-distance parasite transmission 
routes [56, 57]. In contrast to mobile phone data, which 
provide information about movement of the human pop-
ulation, genetic data offer a view on parasite gene flow, 
whose routes may differ from those followed by people. 
Furthermore, genetic data is not restricted to the cover-
age of mobile networks, which is particularly valuable 
across country borders [56, 57].
A classical approach used to quantify connectedness 
between populations is the assessment of genetic differ-
entiation using the fixation index (FST) [58]. This meas-
ure has been used widely in microsatellite-based studies 
of P. falciparum and P. vivax, providing useful insights on 
the connectedness between populations at a moderately 
granular scale [59]. However, FST does not account for 
recombination, and is constrained in its ability to infer 
fine-resolution connectedness [60]. Conversely, measures 
of identity by descent (IBD) apply a probabilistic model 
accounting for recombination and can provide insights 
into more recent demographic changes. IBD is increas-
ingly being used to assess parasite connectedness at 
relatively small spatial scales [60–62]. Tools for measur-
ing IBD include isoRELATE, hmmIBD and DEploid-IBD 
[61–63].
Low-resolution genetic studies of co-endemic P. fal-
ciparum and P. vivax in Indonesia and PNG have dem-
onstrated higher connectedness amongst P. vivax 
populations, highlighting the greater potential for this 
species to spread via the hypnozoite reservoir [64, 65]. 
Rintis Noviyanti, from Eijkman, described plans to 
expand on the maps of parasite connectedness across 
Indonesia using high-throughput SNP-based genotyping 
methods. Alyssa Barry and Livingstone Tavul, from the 
PNG Institute for Medical Research, described similar 
plans for PNG. The evidence generated from these stud-
ies will be shared with the local NMCPs, with a view to 
implementing them more widely within local surveil-
lance frameworks.
Identify imported cases and transmission chains
In low-endemic areas of the Asia–Pacific region, bor-
der malaria and imported cases pose major challenges 
to malaria elimination, particularly in areas with highly 
mobile human populations. Figure 1 illustrates the rela-
tive proportions of autochthonous versus imported 
infections in different countries in the region. The meet-
ing agreed on the importance of distinguishing between 
border and imported malaria, since these reflect dis-
tinct challenges with different surveillance and response 
needs. Duoquan Wang from the National Institute of 
Parasitic Diseases at the Chinese Centre for Disease 
Control, and Yaobao Liu from the Jiangsu Institute for 
Parasitic Diseases, China, described China’s remarkable 
success in reducing indigenous malaria cases from 24 
million in 1970 to zero since 2017 [1], and highlighted 
post-elimination surveillance of border and imported 
malaria as one of the highest priorities for maintaining a 
malaria-free status. Liu described the malaria situation in 
Jiangsu province of central China [66], and the broader 
situation in China, describing how most reported infec-
tions in the past few years were suspected importations 
from Africa (~ 80% P. falciparum) and southeast Asia 
(~ 80% P. vivax) [67]. In several high transmission coun-
tries, there is interest in tools for surveying imported 
cases of P. falciparum from regions such as the GMS 
where artemisinin-resistance is prevalent.
At present, imported cases are usually identified and 
mapped using information on patient travel history. 
However, the procedure followed has been designed 
specifically for P. falciparum malaria, without considera-
tion for the delayed relapses of P. vivax, which may lead 
to incorrect conclusions. Molecular tools to identify 
and map imported malaria cases offer a complemen-
tary approach to traditional epidemiology. Table 2 sum-
marizes different molecular approaches that have been 
used to map imported P. falciparum and P. vivax cases. 
Hidayat Trimarsanto described a collaborative project 
between Eijkman and global partners within the vivax 
Genomic Epidemiology Network (vivaxGEN), to develop 
molecular tools for identifying and mapping imported 
P. vivax cases. Investigation of genomic data from 831 
P. vivax genomes from 20 countries identified 28 new 
genetic markers that can be used to distinguish imported 
from local infections [68]. A web-based tool, vivaxGEN-
GEO, was developed to map country of origin, even in 
the presence of missing or heterozygous genotype calls 
(https ://geo.vivax gen.org/).
Duoquan Wang described the challenge of border 
malaria in Yunnan Province, southern China, which 
shares hundreds of kilometres of border with Myan-
mar [69]. Cross-border parasite flow is high along large 
stretches of the border region, with most cases believed 
to migrate from Myanmar into China; analogous cross-
border flow in Bhutan’s southern districts neighbour-
ing India were reported by Kesang Wangchuk from the 
Ministry of Health, Bhutan. The challenge is more pro-
nounced for P. vivax than P. falciparum, as dormant 
hypnozoites can enable longer persistence of P. vivax 
infections and accordingly wider dispersal. High rates 
of parasite flow across porous border regions result in 
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relatively homogenous parasite populations in neigh-
bouring countries, hampering classification of local from 
imported cases using categorical classification-based 
methods such as vivaxGEN-GEO. Whilst country clas-
sifications may be difficult to obtain using genetic data 
in highly porous border regions, genotyping can poten-
tially be useful to decipher parasite transmission chains; 
using genetic barcodes to distinguish infections, the 
transmission of individual parasite strains can be traced 
from one individual to another. This information can be 
used to monitor whether cases with travel history from 
across the border have been transmitted locally. It was 
agreed by the meeting that genetic homogeneity between 
neighbouring parasite populations poses significant chal-
lenges to monitoring malaria importation and provides 
a strong case for cross-country collaborative efforts and 
data sharing.
Detect HRP2/3‑based rapid diagnostic test failures
Plasmodium falciparum infections with deletions of 
histidine-rich protein 2 and 3 (HRP2 and HRP3) may go 
undetected by several RDTs [70]. Recent insights from 
genomic data on P. falciparum indicate that up to 25% of 
infections in Papua Indonesia and PNG have HRP3 dele-
tions [19], suggesting that molecular surveillance of these 
parasites is needed. However, molecular analysis of HRP2 
and HRP3 variants affecting RDT efficacy remains com-
plex. The WHO recommends PCR-based methods to 
analyse the exons and flanking genes of HRP2 and HRP3, 
and a 7-point quality scoring system based on recom-
mendations by Cheng and colleagues [71]. To date, there 
are no high-throughput frameworks for surveillance of 
these genes.
Characterize outbreaks
Countries with a high burden of malaria have a huge 
challenge in providing robust surveillance systems and 
thus are often not able to assess geospatial and tem-
poral trends such as outbreaks, undermining optimal 
responses to malaria control [1]. Several molecular meth-
ods are available to investigate outbreaks, using methods 
similar to those used for detecting transmission chains. 
Using genetic barcodes to compare infections, it is pos-
sible to identify the rapid clonal expansion of specific 
Fig. 1 Imported case proportions and total malaria case numbers in the Asia–Pacific region in 2018. a presents the percentage of imported 
cases (all species of malaria) in 2018 in order of highest to lowest percentage. b presents the total number of presumed and confirmed cases (for 
all species) in 2018 in the same order as (a). The numbers were derived from the World Malaria Report 2019 summary of reported malaria cases 
by method of confirmation 2010–2018 for countries in the WHO Southeast Asia and Western Pacific region. The percentage of imported cases 
was calculated as the number of imported cases divided by the total number of presumed and confirmed cases. The countries with the highest 
proportion of imported cases have amongst the lowest number of overall cases
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strains, possibly indicating that they possess some fitness 
advantage [49]. Concurrent genotyping at relevant drug 
resistance determinants, geographic markers to identify 
imported cases and HRP deletions can add additional 
information to support such investigations.
Characterize recurrent P. vivax infections
The characterization of recurrent P. vivax infections was 
also deemed to be a genetic use case in the Asia–Pacific 
region. Relapses deriving from dormant liver-stages 
(hypnozoites) are the main contributor to the transmis-
sion of P. vivax infections, as they may be the source of 
over 80% of all cases [72, 73]. Distinguishing relapses 
from reinfections is complex, since hypnozoites causing 
a relapse may be genetically different from the parasites 
that caused the initial infection [74]. Recent studies using 
whole genome sequencing data have demonstrated the 
utility of molecular data to identify recurrent infections 
that are genetically different from day-zero parasites, but 
appear to be related, sharing identity by descent [75, 76]. 
Pairs of day-zero and recurrent parasites that are geneti-
cally related are more likely to have derived from the 
same mosquito bite than from different inoculations (as 
in a reinfection) and are, therefore, more likely to rep-
resent relapse rather than re-infection events. Paired P. 
vivax isolates have been compared using microsatellites 
[119]. Methods using microhaplotypes (short stretches 
of the genome which contain multiple SNPs and, there-
fore, can be treated as a single locus with more than two 
alleles) are also in development [42]. However, whilst 
small sets of microsatellites and microhaplotypes can 
capture genetic similarity due to identity by state (IBS), 
they may miss pairs of siblings that have high IBD (> 50%) 
but low IBS because of recombination. Sasha Siegel, from 
the Wellcome Sanger Institute, described a collaborative 
project with Menzies to develop a comprehensive panel 
of approximately 100 microhaplotypes across the P. vivax 
genome, as an alternative to whole genome sequencing to 
determine which pairs of infections are related based on 
measures of IBD and, therefore, likely to reflect relapse 
events. Mathematical models are being developed to ana-
lyse this information in surveillance frameworks, to infer 
the underlying burden of relapses from passively col-
lected pairs of infections. The aim of this approach is to 
inform on the efficacy of and adherence to primaquine or 
other radical cure policies.
Technical challenges in implementing genotyping 
in-country
Discussions around genotyping use cases highlighted a 
variety of different needs and priorities for parasite sur-
veillance, largely reflecting the varying endemicity across 
the Asia–Pacific region. This raised questions about 
the suitability of a “one size fits all” approach in coun-
tries ranging from high burden areas to only handfuls of 
imported cases (Fig. 1). Each country needs to choose an 
implementation of genetic surveillance that suits their 
needs and maximizes the value they can get from the 
resources they have available. Indeed, the access to spe-
cialized molecular technologies varies widely between 
countries: whilst China is world-renowned for its capa-
bilities, with large sequencing centres providing services 
to clients across the globe, many other countries in the 
region have poor access to genomic services.
The varying access to genomic services fuelled discus-
sion around the pros and cons of whole genome sequenc-
ing for parasite surveillance. In the pros, whole genome 
sequencing provides the highest genetic information 
content on a sample, with the potential to genotype thou-
sands of SNPs, as well as copy number variants (CNVs) 
and other structural rearrangements.
Genomic data also provides the greatest potential to 
characterize and disentangle polyclonal infections using 
methods such as DEploid [63]. With the costs of sequenc-
ing continually falling, whole genome sequencing of 
malaria parasites is becoming increasingly cost-effective. 
However, the cons of whole genome sequencing include 
difficulty in obtaining high-quality samples from patient 
infections, particularly for low-density P. vivax infec-
tions. Although selective whole genome amplification 
(sWGA) methods have been established for P. falciparum 
and P. vivax to overcome the challenges of low-density 
infections and high human DNA contamination [77, 78], 
these methods constrain detection of CNVs, and cov-
erage of the P. vivax genome can remain sparse in low-
quality samples. The biggest constraints to whole genome 
sequencing in many parts of the Asia–Pacific are the lim-
ited technical and bioinformatic skills required to achieve 
high-quality genomic data and to handle and analyse the 
large datasets.
For many of the use cases described, whole genome 
data is unnecessary; carefully selected subsets of SNPs 
(SNP barcodes) or other variants can provide the infor-
mation needed by NMCPs. A range of platforms are 
available for genotyping SNP barcodes, producing data 
that is informative but requires smaller investments 
than whole genome sequencing and is more suitable for 
entry-level expertise. An example of such an approach 
is amplicon sequencing, which performs high-through-
put sequencing, but only at loci of interest. As a result, 
it is more cost effective than whole genome sequencing, 
simpler to analyse, and can still provide a comprehen-
sive profiling of the parasites, by typing drug-resistance 
mutations as well as genetic barcodes that “summarize” 
the genome. A technical session was held to discuss the 
relative pros and cons of amplicon sequencing and other 
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genotyping platforms that are currently being considered 
for parasite surveillance (see Table 3 for a summary).
Olivo Miotto gave an overview of the SpotMalaria 
amplicon sequencing framework and SNP barcodes used 
by the GenRe-Mekong project to genotype P. falcipa-
rum and P. vivax samples (https ://www.malar iagen .net/
proje cts/spotm alari a). An overview of the SpotMalaria 
barcodes and several other Plasmodium SNP barcodes 
is provided in Table 4. Amplicon sequencing uses high-
throughput Illumina sequencers to sequence selected 
loci across the Plasmodium genome, enabling multiplex-
ing that allows hundreds of samples to be genotyped in 
a single experiment, providing cost-effective genotyping 
of large sample sets with high accuracy and sensitivity. 
The sensitivity will depend in part on the multiplexing 
level and other sequencing conditions, but is potentially 
even amenable to leftover clinical material from RDTs 
[79]. The platform is flexible to iterative enhancements 
and extensions of the SNP barcodes. The reliance on 
specialized equipment and reagents, and the need for 
highly skilled technicians, limit amplicon sequenc-
ing implementations to few laboratories, best achieved 
through a centralized genotyping framework within a 
given malaria-endemic country, or regional reference 
laboratories supporting multiple countries. Networks 
such as APMEN, ACREME, vivaxGEN and MalariaGEN 
can support regional efforts, promoting standardization 
and knowledge sharing. The high-throughput nature of 
amplicon sequencing lowers the turnaround time for data 
to be returned, which is typically of the order of weeks or 
months in current implementations. Although this turn-
around is not suitable for supporting point-of-care deci-
sions, it is valuable for use by NMCPs needing to make 
policy decisions based on population-level data. The two 
examples of policy changes in Vietnam were supported 
by population-level genetic data on drug resistance vari-
ants (in collation with clinical data), which is provided to 
the NMCPs (Institute of Malaria, Parasitology and Ento-
mology in Vietnam) on a quarterly basis (approximately 
every 3 months).
Building in-country processing capacity is a primary 
objective of the SpotMalaria and GenRe-Mekong genetic 
surveillance projects. Implementing high-throughput 
pipelines for genetic surveillance promotes ownership of 
the process, extends capacity in countries, and potentially 
delivers more timely products. To facilitate in-country 
implementations, the genotyping framework has been 
engineered using an amplicon sequencing approach, so 
that it can operate on lower-end Illumina sequencers 
and be deployed in malaria-endemic countries. Technol-
ogy transfer is currently at an advanced stage in Ghana, 
the Gambia, Indonesia and Vietnam. Miotto, Nguyen 
Thuy-Nhien and Noviyanti described their respective 
experiences of the pros and cons of amplicon sequencing 
in malaria-endemic countries. In most cases, the adop-
tion process has been gradual, owing to challenges such 
as infrastructure stability (such as electrical power), pro-
curing specialized reagents, and the higher local costs of 
equipment, reagents and maintenance. Several endemic 
countries are not ready to make such a transition, so it 
is essential that they be guaranteed equal access to tech-
nology. For this reason, SpotMalaria and GenRe-Mekong 
have continued offering processing capacity at the Well-
come Sanger Institute, while encouraging labs in endemic 
countries to provide regional processing support for 
neighbouring countries.
Alyssa Barry gave an overview of Oxford Nanopore’s 
minION platform, which supports rapid data delivery, 
potentially within as little as 24 h of sample processing. 
The minION is a highly portable sequencer, which can 
be deployed in low-resource settings, with a lower start-
up investment than Illumina sequencers but also lower 
throughput, which makes it more suitable for processing 
small sets of samples. It is also technically simpler than 
Illumina, requiring less specialized skills. This platform 
can be used for targeted genotyping of SNP barcodes, as 
well as sequencing of large and highly repetitive genomic 
regions. The flexibility to sequence entire regions in a 
non-targeted manner has potential for detecting new 
mutations, but it may be difficult for health workers or 
NMCPs to derive useful interpretations on these muta-
tions. The main technical disadvantage of the minION 
is its sequencing error rate, higher than that of Illumina. 
The high error rate needs correcting by producing mul-
tiple reads covering the locus of interest and applying 
appropriate statistical methods.
In addition to the laboratory aspects of these geno-
typing platforms, there were active discussions around 
the processing and interpretation of the data they pro-
duce. The partners agreed that both the Illumina and 
minION platforms present considerable bioinformat-
ics challenges, highlighting the need for local capacity 
building to support data handling and analysis. Some 
participants identified data processing as a suitable task 
for service provision and placed greater importance on 
data interpretation and the need for user-friendly data 
outputs that can be readily used by control programme 
workers who may have limited knowledge of genetics. 
Data analysis tools are being developed and are build-
ing capacity to address the knowledge gaps between 
researchers and control programmes. However, these 
tools are in their infancy and further optimization and 
development is needed. The SpotMalaria team have 
developed an informatics pipeline to support the analysis 
of amplicon sequencing data uploaded from the Illumina 
sequencer, producing Genetic Report Cards, detailing 
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individual-level information on the presence of muta-
tions that confer resistance to a variety anti-malarial 
drugs in each infection (https ://www.malar iagen .net/
proje cts/spotm alari a). In addition, GenRe-Mekong deliv-
ers reports containing maps of population-level drug 
resistance prevalence for different drugs, shown using 
intuitive “traffic light” colour representations (example 
in Fig.  2). Whilst the importance of user-friendly tools 
for the NMCPs was widely agreed on, there was also a 
keen interest in strengthening the local research capac-
ity. The malaria research outputs from Eijkman provide 
inspiring examples of the potential for developing local 
bioinformatics expertise in the region. Collaborative 
projects between Eijkman and Menzies have established 
web-based, open access genetic data analysis tools such 
as vivaxGEN-GEO [68], vivaxGEN-MS [80], and vivax-
GEN-SNP (in development). The vivaxGEN-MS platform 
currently hosts data from 11 countries and has supported 
data analysis for 10 publications to date. Enhancing local 
research in genetics and genomics will enable countries 
to implement molecular surveillance tools and tailored 
them to specific local needs.
Data sharing within and between countries
The workshop discussed the relevance of data sharing 
to both researchers and NMCPs, along with the chal-
lenges that needed to be addressed. The consensus 
was that data sharing between institutions and across 
national borders is crucial for addressing use cases such 
as drug resistance gene flow, connectivity between pop-
ulations, and border and imported malaria. There were 
no anticipated political obstacles to data sharing within 
countries. However, some countries perceive intellec-
tual property as a potential challenge in sharing data. 
In other countries, such as Indonesia, national export 
restrictions constrain sharing of the raw sequence reads 
generated by whole genome sequencing. Such restric-
tions challenge open access but can be mitigated by 
sharing “intermediate datasets” such as the genotype 
calls used in whole genome sequencing studies, which 
ensures that the results are reproducible (e.g. [81] pro-
vides genotype calls in a vcf file format). Furthermore, 
this ensures that genotyping data produced at micro-
satellites or SNP-based barcodes can be made open 
access. The value of converging on commonly struc-
tured datasets was also discussed; for example, whether 
the broad range of SNP barcodes available for different 
use cases would be a challenge in sharing data between 
sites where there is little or no overlap in the SNP pan-
els. The participants acknowledged that markers tai-
lored to a specific country or region may have higher 
resolution than global marker sets to resolve the local 
genetic microepidemiology; however, they agreed that 
consensus was needed to ensure that at least part of the 
data generated in each country could be shared with 
others to support regional surveillance. For use cases 
such as assessment of transmission intensity, consen-
sus markers would strengthen comparability between 
sites, but are not essential. However, for use cases that 
aim to assess the connectivity or drug resistance gene 
flow between populations, overseas importation, or 
cross-border transmission, a consensus marker set 
is critical. In addition, platforms and tools to support 
data sharing between partners within and across bor-
ders can overcome inability to share data due to a lack 
of mechanisms to do so effectively. Networks such as 
APMEN, ACREME, vivaxGEN, the Worldwide Antima-
larial Resistance Network (WWARN) and MalariaGEN 
are important forums to support consensus and data 
sharing between countries. The APMEN vivax work-
ing group has been successful in establishing consensus 
for microsatellite-based genotyping markers across the 
network, when this technology was still the favoured 
genotyping method for P. vivax [80]. The network has 
also helped establish a platform supporting open-
access sharing of the microsatellite-based genotyping 
data [80]. For SNP-based data, the platform underpin-
ning GenRe-Mekong and SpotMalaria automatically 
aggregates data, presenting regional and global views. 
Data sharing can be integrated into the processing 
pipelines and thus come at no extra effort for the coun-
try. Ownership of the data is retained by the country, 
and adequate recognition and visibilities are given to 
the contributing party when the data are aggregated.
Ethical aspects of genetic surveillance were raised; 
specifically, it was highlighted that patient informed 
consent and assent can add a large additional work-load 
on top of routine tasks. Furthermore, the primary goal 
of surveillance outputs is to inform public health rather 
than to conduct research. In the Lao People’s Demo-
cratic Republic and Thailand, NMCPs are considering 
requesting an exemption from collecting additional 
patient consent, justified by the integration of sample 
collection in the standard treatment procedures, and 
the public health benefits of the resulting outputs. A 
critical condition for such exemption is that no human 
genetic data is collected. Different solutions will have to 
be adopted by countries that deem it important to gen-
otype human genetic variants, for example to establish 
the prevalence of glucose-6-phosphate dehydrogenase 
(G6PD) variants or cytochrome P450 2D6 (CYP2D6) 
variants that have implications for the safe and effective 
administration of primaquine [82].
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Fig. 2 Example of a GenRe‑Mekong drug resistance prevalence “traffic light” plot. Example of a map generated by the SpotMalaria GenRe‑Mekong 
project, showing the predicted prevalence of artemisinin‑resistant parasites at sites in 6 provinces of Vietnam before September 2018. District‑level 
drug resistance‑associated allele frequencies are coloured according to prevalence (ranging from 0–100% in a spectrum from green to red). 
Courtesy of the Institute of Malariology, Parasitology and Entomology, Quy Nhon and OUCRU, Vietnam
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Maximizing the value of parasite genotyping for control 
programmes
The workshop ended with a session on maximizing the 
value proposition of molecular surveillance for malaria 
control programmes. Miotto highlighted that “it’s hard 
to appreciate the value of something you don’t have, and 
hard to predict what you will use in the future”. The full 
value and potential of genotyping tools may only be real-
ized once they are actively implemented within surveil-
lance frameworks on a wider scale. In order to reach 
that stage, the research community needs to ensure that 
they gain a good understanding of NMCPs activities, to 
ensure the molecular applications they develop serve 
these needs optimally. As emphasized by the Indonesian 
NMCPs, regular engagement between local researchers 
and NMCPs will be critical to achieve this. Ferdinand 
Laihad and Endang Sumiwi, from the Indonesian NMCP, 
emphasized the value of bringing together participants 
from different countries to share their local knowledge 
and experiences in malaria control and elimination.
There was active discussion concerning the financing 
of comprehensive surveillance frameworks. To achieve 
the routine and widespread sampling and processing 
needed for an informative surveillance operation, a stable 
source of funding is needed from local governments, the 
WHO, or other international funding agencies. Inclusion 
of genetic epidemiology in WHO policy will be needed 
to leverage funds from the Global Fund. It was widely 
agreed that more evidence of policy changes, as observed 
in Vietnam, and demonstration of the advantages and 
potential cost-saving of genetic surveillance tools are 
needed to encourage increases in funding from local gov-
ernments and other key stakeholders. Large-scale evalu-
ations of the cost-effectiveness of different use cases will 
be invaluable.
Conclusion
The elimination of malaria from the Asia–Pacific region 
by 2030 presents a spectrum of formidable challenges 
and innovative approaches both within and between 
countries are needed. Molecular surveillance offers great 
potential to generate knowledge that will allow NMCPs 
to keep ahead of the constantly changing and evolving 
dynamics of parasite populations. Considerable work is 
still needed to support the implementation of genomic 
technologies and bioinformatics capacity in the region. 
Further research is needed to optimize methodologies 
for several use cases, and to build the evidence base on 
the utility and cost-efficacy of genetic epidemiology, to 
help leverage funding and logistic support for wide-scale 
genetic and genomic surveillance in-country. Engage-
ment between NMCPs and researchers will be critical 
at each step, to ensure that these efforts meet the opera-
tional needs of malaria elimination.
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